For the first six months of this year, the surplus amounted to a good 3.9 billion euros, after a loss of almost 142 million euros in the previous year. Sales in the quarter ended June 30th were estimated at around EUR 5.3 billion, after EUR 41.7 million in the previous year. For the first half of the year this resulted in total sales of almost 7.4 billion euros, after a good 69 million euros in the same period of the previous year.
The German biopharmaceutical company is forecasting sales revenues of 15.9 (previously: 12.4) billion euros with the Covid vaccine. And it could be even more, because the current sales forecast is based on the contracts signed by July 21 for the delivery of around 2.2 billion vaccine doses by the end of the year.
“Additional sales are expected in connection with further supply contracts for deliveries in 2021, with the first contracts for 2022 and beyond have already been concluded,” said the Mainz-based company on Monday.
US partner Pfizer had already raised its sales forecast for the vaccine at the end of July after further supply contracts were concluded. According to BioNTech, production of 3 billion cans is now targeted by the end of the year. In 2022 it should then be up to 4 billion units. As of July 21, more than a billion vaccine doses had been delivered to more than 100 regions.
Regarding a possible booster vaccination, the company said, “BioNTech and Pfizer believe that a booster or third dose of BNT162b2 has the potential to maintain the highest level of protection against all variants currently tested, including Delta.” In the coming weeks, more precise data from the analysis of ongoing clinical studies are to be published and submitted to the regulatory authorities in the USA, the European Union (EU) and other countries.
BioNTech and Pfizer had received the world’s first approval for a Covid-19 vaccine at the end of 2020, and business with the vaccine spurred the German company. In the second quarter, BioNTech achieved sales of 5.31 billion euros thanks to the vaccines business, after 41.7 million euros in the same period of the previous year. The net profit was 2.79 billion euros, after a loss of 88.3 million a year earlier.
On the stock exchange, investors applauded the higher annual forecast: BioNTech shares soared 6.5 percent after the publication of the quarterly figures and left the index of European health stocks far behind.
Jane Stock is a technology author, who has written for 24 Hours World. She writes about the latest in technology news and trends, and is always on the lookout for new and innovative ways to improve his audience’s experience.
